2018/03/27 by Jeong Il Yu, Gyu Sang Yoo, Sungkoo Cho +13 · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Hepatocellular Carcinoma Treatment and Prognosis #Cancer, Hypoxia, and Metabolism #Cholangiocarcinoma and Gallbladder Cancer Studies
paper · pdf · doi:10.3857/roj.2017.00409
openalex publication_date 2018/03/27 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
PURPOSE: This study aimed to evaluate the initial outcomes of proton beam therapy (PBT) for hepatocellular carcinoma (HCC) in terms of tumor response and safety. MATERIALS AND METHODS: HCC patients who were not indicated for standard curative local modalities and who were treated with PBT at Samsung Medical Center from January 2016 to February 2017 were enrolled. Toxicity was scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Tumor response was evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST). RESULTS: . Liver function status was not significantly affected after PBT. Greater than 80% of patients had Child-Pugh class A and albumin-bilirubin (ALBI) grade 1 up to 3-months after PBT. Of 78 patients followed for three months after PBT, infield complete and partial responses were achieved in 54 (69.2%) and 14 (17.9%) patients, respectively. CONCLUSION: PBT treatment of HCC patients showed a favorable infield complete response rate of 69.2% with acceptable acute toxicity. An additional follow-up study of these patients will be conducted.